| |
Clinical benefit (n=8)
|
No clinical benefit (n=29)
|
p-value
|
|---|
|
Total Doses
|
33.0 (29.0 – 41.75)
|
18.0 (12.5 – 28.0)
|
.001*
|
|
Total Cycles
|
6.0 (5.0 – 6.0)
|
2.0 (2.0 – 4.0)
|
<.001*
|
|
Doses per Cycle
|
6.4 (5.33 – 6.96)
|
7.0 (5.42 – 7.38)
|
.502*
|
|
Duration (months)
|
26.0 (18.25 – 56.25)
|
1.0 (0 – 4.0)
|
<.001*
|
|
Peak Fever (Celsius)
|
39.7 (38.5 – 40.3)
|
39.1 (38.4 – 39.3)
|
.158*
|
|
Peak ALC
|
3.75 (2.85 – 5.425)
|
2.9 (1.9 – 4.05)
|
.137*
|
|
Platelets
|
50.0 (37.25 – 93.0)
|
80.0 (69.5 – 133.0)
|
.015*
|
|
Autoimmune phenomenon
|
4 (50.0%)
|
4 (13.8%)
|
.049†
|
|
Any Toxicity
|
5 (62.5%)
|
9 (31.0%)
|
.215†
|
|
None
|
3 (37.5%)
|
20 (68.9%)
|
.215†
|
|
Grade 3
|
3 (37.5%)
|
3 (10.3%)
|
.101†
|
|
Grade 4
|
2 (25.0%)
|
6 (20.7%)
|
.1.0†
|
|
Grade 5
|
--
|
--
|
--
|
|
Survived
|
6 (75.0%)
|
7 (24.1%)
|
.006†
|
|
Survival Months
|
61.0
|
17.0
|
.001¥
|
-
†Fisher’s Exact test (reported as frequency (percent)).
- *Mann–Whitney U (reported as median (interquartile range)).
-
¥Log-Rank Test (reported as median, censored data included).
- ALC: Absolute Lymphocyte Count.
